Search Results - "Zerbini, A"

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial by Miller, Paul D, Hattersley, Gary, Riis, Bente Juel, Williams, Gregory C, Lau, Edith, Russo, Luis Augusto, Alexandersen, Peter, Zerbini, Cristiano A. F, Hu, Ming-yi, Harris, Alan G, Fitzpatrick, Lorraine A, Cosman, Felicia, Christiansen, Claus

“…IMPORTANCE: Additional therapies are needed for prevention of osteoporotic fractures. Abaloparatide is a selective activator of the parathyroid hormone type 1…”
Get full text

Global dietary calcium intake among adults: a systematic review by Balk, E. M., Adam, G. P., Langberg, V. N., Earley, A., Clark, P., Ebeling, P. R., Mithal, A., Rizzoli, R., Zerbini, C. A. F., Pierroz, D. D., Dawson-Hughes, B.

“…Low calcium intake may adversely affect bone health in adults. Recognizing the presence of low calcium intake is necessary to develop national strategies to…”
Get full text

Early kinetics of innate and adaptive immune responses during hepatitis B virus infection by Fisicaro, P, Valdatta, C, Boni, C, Massari, M, Mori, C, Zerbini, A, Orlandini, A, Sacchelli, L, Missale, G, Ferrari, C

“…Innate immunity appears to be silent in acutely hepatitis B virus (HBV)-infected chimpanzees, as shown by microarray analysis of intrahepatic gene expression…”
Get more information

Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active‐Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial by Brown, Jacques P., Engelke, Klaus, Keaveny, Tony M., Chines, Arkadi, Chapurlat, Roland, Foldes, A. Joseph, Nogues, Xavier, Civitelli, Roberto, De Villiers, Tobias, Massari, Fabio, Zerbini, Cristiano A.F., Wang, Zhenxun, Oates, Mary K., Recknor, Christopher, Libanati, Cesar

“…ABSTRACT The Active‐Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial (NCT01631214;…”
Get full text

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment by Fleischmann, Roy, Schiff, Michael, van der Heijde, Désirée, Ramos‐Remus, Cesar, Spindler, Alberto, Stanislav, Marina, Zerbini, Cristiano A. F., Gurbuz, Sirel, Dickson, Christina, de Bono, Stephanie, Schlichting, Douglas, Beattie, Scott, Kuo, Wen‐Ling, Rooney, Terence, Macias, William, Takeuchi, Tsutomu

“…Objective We undertook this phase III study to evaluate baricitinib, an orally administered JAK‐1/JAK‐2 inhibitor, as monotherapy or combined with methotrexate…”
Get full text

Biologic therapies and bone loss in rheumatoid arthritis by Zerbini, C. A. F., Clark, P., Mendez-Sanchez, L., Pereira, R. M. R., Messina, O. D., Uña, C. R., Adachi, J. D., Lems, W. F., Cooper, C., Lane, N. E.

“…Introduction Rheumatoid arthritis (RA) is a common systemic autoimmune disease of unknown cause, characterized by a chronic, symmetric, and progressive…”
Get full text

Romosozumab Treatment in Postmenopausal Women with Osteoporosis by Cosman, Felicia, Crittenden, Daria B, Adachi, Jonathan D, Binkley, Neil, Czerwinski, Edward, Ferrari, Serge, Hofbauer, Lorenz C, Lau, Edith, Lewiecki, E. Michael, Miyauchi, Akimitsu, Zerbini, Cristiano A.F, Milmont, Cassandra E, Chen, Li, Maddox, Judy, Meisner, Paul D, Libanati, Cesar, Grauer, Andreas

“…Romosozumab binds sclerostin, increases bone formation, and decreases bone resorption. Postmenopausal women with osteoporosis were assigned to romosozumab or…”
Get full text

Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial by Geusens, Piet, Marin, Fernando, Kendler, David L, Russo, Luis A, Zerbini, Cristiano AF, Minisola, Salvatore, Body, Jean Jacques, Lespessailles, Eric, Greenspan, Susan L, Bagur, Alicia, Stepan, Jan J, Lakatos, Péter, Casado, Enrique, Moericke, Rüdiger, López‐Romero, Pedro, Fahrleitner‐Pammer, Astrid

“…ABSTRACT The 2‐year, randomized, double‐blind, active‐controlled fracture endpoint VERO study included postmenopausal women with established osteoporosis, who…”
Get full text

Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment by Schiff, Michael, Takeuchi, Tsutomu, Fleischmann, Roy, Gaich, Carol L, DeLozier, Amy M, Schlichting, Douglas, Kuo, Wen-Ling, Won, Ji-Eon, Carmack, Tara, Rooney, Terence, Durez, Patrick, Shaikh, Saeed, Hidalgo, Rodolfo Pardo, van Vollenhoven, Ronald, Zerbini, Cristiano A F

“…This study evaluates patient-reported outcomes (PROs) in a double-blind, phase III study of baricitinib as monotherapy or combined with methotrexate (MTX) in…”
Get full text

Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs by Charles-Schoeman, Christina, Burmester, Gerd, Nash, Peter, Zerbini, Cristiano A F, Soma, Koshika, Kwok, Kenneth, Hendrikx, Thijs, Bananis, Eustratios, Fleischmann, Roy

“…Biological disease-modifying antirheumatic drugs (bDMARDs) have shown diminished clinical response following an inadequate response (IR) to ≥1 previous bDMARD…”
Get more information

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures by Austin, Matthew, Yang, Yu-Ching, Vittinghoff, Eric, Adami, Silvano, Boonen, Steven, Bauer, Douglas C, Bianchi, Gerolamo, Bolognese, Michael A, Christiansen, Claus, Eastell, Richard, Grauer, Andreas, Hawkins, Federico, Kendler, David L, Oliveri, Beatriz, McClung, Michael R, Reid, Ian R, Siris, Ethel S, Zanchetta, Jose, Zerbini, Cristiano AF, Libanati, Cesar, Cummings, Steven R

“…Dual‐energy X‐ray absorptiometric bone mineral density (DXA BMD) is a strong predictor of fracture risk in untreated patients. However, previous patient‐level…”
Get full text

Aqueous tap and rapid diagnosis of cytomegalovirus anterior uveitis: the Reggio Emilia experience by De Simone, L., Belloni, L., Aldigeri, R., Zerbini, A., Mastrofilippo, V., Sangiovanni, A., Parmeggiani, M., Fontana, L., Cimino, Luca

“…Purpose The diagnosis of cytomegalovirus (CMV) anterior uveitis in immunocompetent patients requires confirmation by polymerase chain reaction (PCR) analysis…”
Get full text

Effects of Up to 5 Years of Denosumab Treatment on Bone Histology and Histomorphometry: The FREEDOM Study Extension by Brown, Jacques P, Reid, Ian R, Wagman, Rachel B, Kendler, David, Miller, Paul D, Jensen, Jens‐Erik Beck, Bolognese, Michael A, Daizadeh, Nadia, Valter, Ivo, Zerbini, Cristiano AF, Dempster, David W

“…ABSTRACT Denosumab reduced bone resorption, increased bone mineral density (BMD), and decreased new vertebral, hip, and nonvertebral fracture risk in…”
Get full text

Could different aqueous humor and plasma cytokine profiles help differentiate between ocular sarcoidosis and ocular tuberculosis? by De Simone, L., Bonacini, M., Aldigeri, R., Alessandrello, F., Mastrofilippo, V., Gozzi, F., Bolletta, E., Adani, C., Zerbini, A., Cavallini, G. M., Fontana, L., Salvarani, C., Croci, S., Cimino, L.

“…Objective and design A cross-sectional single-center study was conducted to assess cytokine levels in aqueous humor (AH) and plasma of three different uveitis…”
Get full text

A HERITAGE INVENTORY FOR DOCUMENTING ENDANGERED ARCHAEOLOGY IN THE MIDDLE EAST AND NORTH AFRICA by Sheldrick, N., Zerbini, A.

“…The heritage of the Middle East and North Africa is under growing threat from a variety of factors, including agricultural expansion, urban development,…”
Get full text

Vogt–Koyanagi–Harada patients show higher frequencies of circulating NKG2Dpos NK and NK T cells by Bonacini, M., Cimino, L., De Simone, L., Bolletta, E., Gozzi, F., Soriano, A., Muratore, F., Zerbini, A., Fontana, L., Salvarani, C., Croci, S.

“…Vogt Koyanagi Harada patients show higher frequencies of NKG2Dpos NK and NKT cells. IL‐4, IL‐5, IL‐7, IL‐17 and PDGF‐bb are higher in plasma of Vogt Koyanagi…”
Get full text

Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women With Osteoporosis: 5‐Year Data From the Phase 3 Long‐Term Odanacatib Fracture Trial (LOFT) and its Extension by Recker, Robert, Dempster, David, Langdahl, Bente, Giezek, Hilde, Clark, Seth, Ellis, Graham, Villiers, Tobias, Valter, Ivo, Zerbini, Cristiano AF, Cohn, Dosinda, Santora, Arthur, Duong, Le T

“…ABSTRACT Odanacatib (ODN), a selective oral inhibitor of cathepsin K, was an investigational agent previously in development for the treatment of osteoporosis…”
Get full text

Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial by Coombs, J H, Bloom, B J, Breedveld, F C, Fletcher, M P, Gruben, D, Kremer, J M, Burgos-Vargas, R, Wilkinson, B, Zerbini, C A F, Zwillich, S H

“…To determine the efficacy of CP-690,550 in improving pain, function and health status in patients with moderate to severe active rheumatoid arthritis (RA) and…”
Get more information

Reggio Emilia (Northern Italy) Interdisciplinary Uveitis Clinic: What We Have Learned in the Last 20 Years by Gentile, P, Aldigeri, R, Mastrofilippo, V, Bolletta, E, De Simone, L, Gozzi, F, Ragusa, E, Ponti, L, Adani, C, Zanelli, M, Belloni, L, Bonacini, M, Croci, S, Zerbini, A, De Maria, M, Neri, A, Vecchi, M, Cappella, M, Fastiggi, M, De Fanti, A, Citriniti, G, Crescentini, F, Galli, E, Muratore, F, Montepietra, S, Contardi, G, Massari, M, Paci, M, Facciolongo, N C, Beltrami, M, Cavallini, G M, Salvarani, C, Cimino, L

“…To analyze the referral patterns and the clinical and therapeutic features of patients diagnosed with uveitis in an Italian tertiary referral center to provide…”
Get full text

L-Asparaginase and inhibitors of glutamine synthetase disclose glutamine addiction of β-catenin-mutated human hepatocellular carcinoma cells by Tardito, S, Chiu, M, Uggeri, J, Zerbini, A, Da Ros, F, Dall'Asta, V, Missale, G, Bussolati, O

“…Selected oncogenic mutations support unregulated growth enhancing glutamine availability but increasing the dependence of tumor cells on the amino acid. Data…”
Get more information